Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Singer

Showing results (671-680 of 771) with videos related to

Pageof 78
Sort By:
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 18, 2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) RegistryBenjamin A Steinberg, Sunghee Kim, Jonathan P Piccini, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Chest|February 9, 2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesJohn J You, Daniel E Singer, Patricia A Howard, et al.
Pageof 78

Showing results (671-680 of 771) with videos related to

Sort By:
Pageof 78
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Journal of the American Heart Association|June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF TrialGeorge C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)|March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
The American Journal of Cardiology|September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 18, 2013
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) RegistryBenjamin A Steinberg, Sunghee Kim, Jonathan P Piccini, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
Journal of the American College of Cardiology|March 19, 2013
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trialJonathan P Piccini, Susanna R Stevens, Yuliya Lokhnygina, et al.
Stroke|April 26, 2014
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialKa Sing Lawrence Wong, Dai Yi Hu, Abraham Oomman, et al.
Chest|February 9, 2012
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesJohn J You, Daniel E Singer, Patricia A Howard, et al.
Pageof 78